Skip to content

DMT: all studies

Page 58 of 160: studies 571 to 580 of 1,593, newest first. Back to the DMT overview

Research

Exploring Endogenous Tryptamines: Overlooked Agents Against Fibrosis in Chronic Disease? A Narrative Review

Livers December 27, 2024 Hunter W. Korsmo

Long regarded as illicit substances with no clinical value, N-dimethylated tryptamines—such as N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and bufotenine—have been found to produce naturally in a wide variety of species, including humans. Known for their psychoactive effects through serotonin receptors (5-HTRs), N-dimethylated tryptamines are currently being reinvestigated...

DOI: 10.3390/livers4040043 (opens in new tab) Full text (opens in new tab) DMT <i>n</i>-methylated tryptamines Fibrosis Inmt +2

Exploring the regulatory framework of psychedelics in the US & Europe.

Asian Journal of Psychiatry December 1, 2024 Hitesh Kumar Behera, Ramesh Joga, Sravani Yerram et al.

Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory...

Psychedelic research, assisted therapy and the role of the anaesthetist: A review and insights for experimental and clinical practices.

British Journal of Clinical Pharmacology December 1, 2024 Gisela Lima, Carla Soares, Marta Teixeira et al. 4 citations

Recent years have witnessed an unprecedented increase in the search for the use of psychedelics in improving physical and mental health. Anaesthesia has evolved since very early times, born from the need to eliminate pain and reduce suffering and there are reports of the use of anaesthetics to achieve mystical states since the nineteenth century. Nowadays, the renaissance of psychedelics in...

Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty.

Multiple sclerosis and related disorders December 1, 2024 Tarunya Arun, Kate Petheram, Emma Tallantyre et al.

Therapeutics of neuroinflammatory disorders including multiple sclerosis is one of the fastest growing areas in neurology. However, pressures on higher specialty training in neurology together with an expanding curriculum have led to challenges in adequately preparing trainees for a subspecialist career. In this study we set out to understand current perceptions and barriers to training in...

DOI: 10.1016/j.msard.2024.106144 (opens in new tab) Full text (opens in new tab) DMT Medical-education Neurological-training Multiple-sclerosis-care +6

Ayahuasca: pharmacology, safety, and therapeutic effects.

CNS Spectrums November 20, 2024 Rafael Guimarães Dos Santos, Jaime Eduardo Cecilio Hallak 13 citations

Ayahuasca is a botanical hallucinogen traditionally used for therapeutic and ritual purposes by indigenous groups from Northwestern Amazonian countries such as Brazil, Peru, Colombia, and Ecuador. Ayahuasca is made by the decoction of two plants, which are rich in the 5-HT1A/2A partial agonist dimethyltryptamine or DMT (from the leaves of the Psychotria viridis bush) and β-carbolines such as...

The anxiolytic-like effect of the alkaloid fraction of the psychedelic plant Mimosa tenuiflora (Willd.) Poir.

Natural Product Research September 18, 2024 Jady Vitoria Barjud Pereira Ferreira, Ana Marcia de Freitas Pessoa, Rita de Cassia de Lima Sousa et al. 1 citation

The present work investigated the anxiolytic effect of the alkaloid fraction (AF II) from the root bark of Mimosa tenuiflora. Female Swiss mice of 6 weeks old were used in this study. The animals were divided into three groups: 0.9% NaCl (vehicle group, s.c.), AF II (6 mg/kg, s.c.), and diazepam - DZP (5 mg/kg, s.c.). The light/dark box and elevated plus maze tests evaluated the animal anxiety....

Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.

Pharmacological Research September 1, 2024 Giorgia Caspani, Simon Ruffell, WaiFung Tsang et al. 13 citations

Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around their partial agonism at the serotonin 2 A receptor, leading to enhanced neuroplasticity and brain connectivity changes that underlie positive mindset shifts. However, these accounts fail to recognise that the gut microbiota, acting via the gut-brain...

The Role of Ayahuasca in Colorectal Adenocarcinoma Cell Survival, Proliferation and Oxidative Stress.

Pharmaceuticals June 2, 2024 Joana Gonçalves, Mariana Feijó, Sílvia Socorro et al.

The psychedelic beverage ayahuasca is originally obtained by Banisteriopsis caapi (B. caapi) (BC) and Psychotria viridis (P. viridis) (PV). However, sometimes these plant species are replaced by others that mimic the original effects, such as Mimosa hostilis (M. hostilis) (MH) and Peganum harmala (P. harmala) (PH). Its worldwide consumption and the number of studies on its potential therapeutic...

Unlocking the biosynthesis of psychedelic-inspired indolethylamines.

Trends in biochemical sciences March 1, 2024 Abhishek K. Sen, J. Andrew Jones 2 citations

A recent report by Chen et al. describes the discovery of RmNMT, a highly active and promiscuous tryptamine N-methyltransferase from the cane toad, Rhinella marina. N,N-dimethyltryptamine derivatives produced by this enzyme were then evaluated for their potential to serve as next-generation treatments for mental health disorders.

DOI: 10.1016/j.tibs.2023.12.009 (opens in new tab) Full text (opens in new tab) N-dimethyltryptamine N-methylation Psychedelic indolethylamine Serotonin receptor binding +4

Emotion regulation effects of Ayahuasca in experienced subjects during implicit aversive stimulation: An fMRI study.

Journal of Ethnopharmacology February 10, 2024 Tiago Arruda Sanchez, Lucas Rego Ramos, Felipe Araujo et al. 12 citations

Ayahuasca is a beverage used in Amazonian traditional medicine and it has been part of the human experience for millennia as well as other different psychoactive plants. Although Ayahuasca has been proposed as potentially therapeutic as an anxiolytic and antidepressant, whilst no studies have been carried out so far investigating their direct effect on brain emotional processing. This study...